Our cells rely on tightly regulated signaling pathways to control when they grow, divide and survive. When these regulatory ...

Retrospective single-center review of 80 HFrEF patients added SGLT2 inhibitors on stable guideline-directed therapy, with ...

Lilly presented Phase I data from the type II JAK inhibitor, showing good efficacy and safety.

JAK inhibitors show effectiveness and persistence in routine care of adults with rheumatoid arthritis, and cautious patient selection under new recommendations is linked to safer outcomes.

PARP inhibitors reshaped oncology when they first reached patients some 10 years ago, but they represent just one entry point into a much larger and more intricate biological network.

A high-throughput cytometry workflow consolidates marker expression, proliferation, and cytokine release into a single assay ...

When researchers use an inhibitor to block a kinase’s activity, they generally expect to see less of the downstream effects of that kinase. So when neuroscientists observed the opposite using a new ...

Cytokines function as communication tools of the immune system, serving critical functions in many biological responses and shaping the immune response. When cytokine production or their biological ...

Cyclin-dependent kinase (CDK) 4/6 inhibition in combination with endocrine therapy is the standard-of-care treatment for patients with advanced-stage hormone receptor-positive, HER2 non-amplified (HR ...

For many people diagnosed with cancer, treatment with immune checkpoint inhibitors (ICIs) has dramatically extended lives. Some of these treatments, such as Keytruda and Opdivo, have become familiar ...

A new Peter Mac study using a pioneering drug has successfully controlled the growth of tumors and overcome existing drug resistance in multiple cancer types. An enzyme critically associated with ...

A phase I study of irinotecan combined with BAY1895344 (ATR inhibitor) in advanced solid tumors: Results of ETCTN 10402 dose escalation. Focus on human epidermal growth factor receptor 2 (HER2) ...